## BEST AVAILABLE COPY

946644

FORM D

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 30549

OMB APPROVAL	



## FORM D

## NOTICE OF SALE OF SECURITIES PURSUANT TO REGULATION D SECTION 4(6), AND/OR UNIFORM LIMITED OFFERING EXEMPTION

	SEC	USE ONLY
Prefix		Serial
	-	ļ
	DATE	ERECEIVED
	1	1

Name of Offering ( check if this is an amendment and name has changed, and indicate change.)				
Hemispherx Biopharma, Inc.				
File Under (Check box(es) that apply) Rule 504 Rule 505X Rule	e 506 Section 4(6) ULOE			
Type of Filing: X New Filing Amendment				
A. BASIC IDENTIFICATION DA	TA			
Enter the information requested about the issuer				
Name of Issuer ( check if this is an amendment and name has changed, and indicate	e change.)			
Hemispherx Biopharma, Inc.				
Address of Executive Offices (Number and Street, City, State, Zip Code)	Telephone Number (Including Area Code)			
1617 JFK Boulevard Philadelphia, Pennsylvania 19103	(215) 988-0080			
Address of Principal Business Operations (Number and Street, City, State, Zip Code) (If different from Executive Offices)	Telephone Number (Including Area Code)			
Brief Description of Business: A pharmaceutical research and development compar	ny using nucleic acid technologies to develop			
therapeutic products for the treatment of certain viral diseases and cancers.				
Type of Business Organization				
X corporation limited partnership, already formed	_ other (please specify) limited liability			
business trust limited partnership, to be formed	company			
Month	Year			
Actual or Estimated Date of Incorporation or Organization: 12	90 X Actual Estimated			
Jurisdiction of Incorporation or Organization: (Enter two letter U.S. Postal Service abb	reviation for State			
PROCEDIAda; FN for other foreign jur	isdiction) DE			
AUG 1.9.2004	RECEIVED			
CENTED AL DICEPLICATION OF	AST MECEIALD FOW			
THOMSON S				
Federal: FINANCIAL /	aug 1 / 2003 page			
Who Must File: All issuers making an offering of securities in reliance on an exemption under Regulation D or S	ection 4(6), 17 CFR 230.501 et seq. or 15 U.S.C. 77d(6)			
When To File: A notice must be filed no later than 15 days after the first sale of securities in the offering. A n	otice is deemed filed with the U.S. Securifies and Exchange			
Commission (SEC) on the earlier of the date it is received by the SEC at the address given below or, if received at that address after the date in the				
was mailed by United States registered of certified mail to that address.				
Where to File. U.S. Securities and Exchange Commission, 450 Fifth Street, N.W., Washington, D.C. 20549.				
Copies Required: Five (5) copies of this notice must be filed with the SEC, one of which must be manually signed copy or bear typed or printed signatures,	ned. Any copies not manually signed must be photocopies of			
Information Required. A new filing must contain all information requested. Amendments need only report the information requested in Part C, and any material changes from the information previously supplied in Parts A SEC.				
Filing Fee. There is no federal filing fee.				

ATTENTION

appropriate states in accordance with state law. The Appendix to the notice constitutes a part of this notice and must be completed.

This notice shall be used to indicate reliance on the Uniform Limited Offering Exemption (ULOE) for sales of securities in those states that have adopted ULOE and that have adopted this form. Issuers relying on ULOE must file a separate notice with the Securities Administrator in each state where sales are to be, or have been made. If a state requires the payment of a fee as a precondition to the claim for the exemption, a fee in the proper amount shall accompany this form. This notice shall be filed in the

Failure to file notice in the appropriate states will not result in a loss of the federal exemption. Conversely, failure to file the appropriate federal notice will not result in a loss of an available state exemption unless such exemption is predicated on the filing of a federal notice.

A. BASIC IDENTIFICATION DATA							
<ul> <li>2. Enter the information requested for the following:</li> <li>Each promoter of the issuer, if the issuer has been organized within the past five years;</li> <li>Each beneficial owner having the power to vote or dispose, or direct the vote or disposition of, 10% or more of a class of equity securities of the issuer;</li> <li>Each executive officer and director of corporate issuers and of corporate general and managing partners of partnership issuers; and</li> <li>Each general and managing partner of partnership issuers</li> </ul>							
	General and/or						
Tall Name (Last name Cast (Girdicidae)) Contan William A	Managing Partner						
Full Name (Last name first, if individual) Carter, William A.  Business or Residence Address (Number and Street, City, State, Zip Code)							
1617 JFK Boulevard Philadelphia, Pennsylvania 19103							
Check box(es) that Apply: Promoter Beneficial Owner _X_Executive Officer Director	General and/or Managing Partner						
Full Name (Last name first, if individual) Peterson, Robert							
Business or Residence Address (Number and Street, City, State, Zip Code) 1617 JFK Boulevard Philadelphia, Pennsylvania 19103							
Check box(es) that Apply: Promoter Beneficial Owner Executive OfficerX Director O	General and/or maging Partner						
Full Name (Last name first, if individual) Piani, Richard C							
Business or Residence Address (Number and Street, City, State, Zip Code)  11 Boulevard General Koenig Neuilly Sur Siene France 92200							
	General and/or						
Full Name (Last name first, if individual) Mitchell, William M							
Business or Residence Address (Number and Street, City, State, Zip Code) 3901 West End Ave, The Rokeby/ Box 43 Nashville, TN 37205							
· · · · · · · · · · · · · · · · · · ·	General and/or anaging Partner						
Full Name (Last name first, if individual Etheridge, Ransom W							
Business or Residence Address (Number and Street, City, State, Zip Code) 2610 Potters Rd., Virginia Beach, Va 23452							
Check box(es) that Apply: Promoter Beneficial Owner Executive Officer X_ Director Ma	General and/or anaging Partner						
Full Name (Last name first, if individual) Kiani, Iraj E.							
Business or Residence Address (Number and Street, City, State, Zip Code)  18800 Delaware Street, Suite 900 Huntingdon Beach, CA 92648							
Check box(es) that Apply: Promoter Beneficial OwnerExecutive Officer X_ Director	_General and/or						
Full Name (Last name first, if individual) Esteve, Antoni	anaging Partner						
Business or Residence Address (Number and Street, City, State, Zip Code)							
Laboratorios Del Dr. Esteve S.A., AV. Mare de Deu de Montserat, Barcelona, 08041, Spain							
	_General and/or anaging Partner						
Full Name (Last name first, if individual)							
Business or Residence Address (Number and Street, City, State, Zip Code)							
Check box(es) that Apply: Promoter Beneficial OwnerExecutive Officer Director Ma	General and/or anaging Partner						
Full Name (Last name first, if individual)							
Business or Residence Address (Number and Street, City, State, Zip Code)							

					В.	INFORM	MATION	ABOUT	OFFERIN	IG			
1.	Has the issuer sold, or does the issuer intend to sell, to non-accredited investors in this offering?												
2.	What	is the mir	imum inv	estment th	at will be	accepted	from any i	ndividual	?				. \$ <u>49,000</u>
3.	Yes No Does the offering permit joint ownership of a single unit?												
4.													
Bu	siness o	r Residen	ce Addres	s (Numbe	r and Stre	et, City, S	tate, Zip (	Code)	<del></del>	<u> </u>		·- <u></u>	
520	0 Madis	on Avenu	ie, 12 <sup>th</sup> Flo	oor, New Y	ork, NY	10022							
			Broker or										
Jei	fferies	& Comp	any, Inc	<b>,</b>									
				Has Solic		tends to So	olicit Purc	hase				[37]	I A 11 C4-4-
[ [	neck A [AL] [IL] [MT] [RI]	[AK] [IN] [NE] [SC]	[AZ] [IA] [NV] [SD]	individual [AR] [KS] [NH] [TN]	[CA] [KY] [NJ] [TX]	[CO] [LA] [NM] [UT]	[CT] [ME] [NY] [VT]	[DE ] [MD] [NC ] [VA ]	[DC] [MA] [ND] [WA]	[FL ] [MI ] [OH] [WV]	[GA] [MN] [OK] [WI]	[X] [HI ] [MS] [OR ] [WY]	JAll States [ID ] [MO] [PA ] [PR ]
Fu	ll Name	(Last nai	ne first, if	individua	l)								
Business or Residence Address (Number and Street, City, State, Zip Code)													
Na	me of A	ssociated	Broker or	r Dealer									
(C	heck "A			l Has Solic individual	States) .				. ,			_	All States
ĺ	[AL ] [IL ] [MT] [RI ]	[AK ] [IN ] [NE ] [SC ]	[AZ ] [IA ] [NV ] [SD ]	[AR ] [KS ] [NH ] [TN ]	[CA] [KY] [NJ] [TX]	[CO ] [LA ] [NM] [UT ]	[CT] [ME] [NY] [VT]	[DE ] [MD] [NC ] [VA ]	[DC ] [MA] [ND ] [WA]	[FL ] [MI ] [OH] [WV]	[GA] [MN] [OK] [WI]	[HI ] [MS] [OR ] [WY]	[ID ] [MO] [PA ] [PR ]
Full Name (Last name first, if individual)													
Business or Residence Address (Number and Street, City, State, Zip Code)													
			Broker of										
States in Which Person Listed Has Solicited or Intends to Solicit Purchases (Check "All States" or check individual States)													
	[AL ] [IL ] [MT]	[AK] [IN] [NE]	[AZ] [IA] [NV]	[AR] [KS] [NH]	[CA] [KY] [NJ]	[CO] [LA] [NM]	[CT] [ME] [NY]	[DE ] [MD] [NC ]	[DC] [MA] [ND]	[FL] [MI] [OH]	[GA] [MN] [OK]	[HI ] [MS] [OR ]	[ID ] [MO] [PA ]

	C. OFFERING PRICE, NUMBER OF INVESTORS, EXPENSES				8
1.	Enter the aggregate offering price of securities included in this offering and the total Enter "O" if answer is "none" or "zero." If the transaction is an exchange offering,	al am check	ount already sold	i. d	
	indicate in the columns below the amounts of the securities offered for exchange and al			u	
	Type of Security	•	Aggregate Offering Price		ount Already Sold
	Debt	\$	· · · · · · · · · · · · · · · · · · ·	\$_	
	Equity	\$	see Other	\$	
	x Common Preferred				
	Convertible Securities (including warrants).	\$	see Other	_	\$.
	Partnership Interests	\$		. \$	
	Other (Specify)(Shares of Common Stock and Common Stock Warrants)				
	Total	\$ <u>7</u>	,523,996	\$ <u>_7</u>	,523,996
2.	Answer also in Appendix, Column 3, if filing under ULOE. Enter the number of accredited and non-accredited investors who offering and the aggregate dollar amount of their purchases. For number of persons who have purchased securities and the aggregate of the total lines. Enter "0" if answer is "none" or "zero.	offe	rings under 5	04, i eir pi	ndicate the
	Accredited Investors	_	13	_	\$ <u>7,523,996</u>
	Non-accredited Investors	_	0	_ \$	0
	Total (for filings under Rule 504 only)		0	\$	0
3.	If this filing is for an offering under Rule 504 or 505, enter the information reques issuer, to date, in offerings of the types indicated, in the twelve (12) months prior to offering. Classify securities by type listed in Part C - Question 1.	sted for the fi	rst sale of securi	ties in	y the this ollar Amount
	Type of Security NOT APPLICABLE		Type of Security	D	Sold
	Rule 505	. \$		_ \$_	
	Regulation A			\$_	
	Rule 504			\$_	
	Total	\$		\$	
to	a. Furnish a statement of all expenses in connection with the issuance and disfering. Exclude amounts relating solely to organization expenses of the issuer. The infuture contingencies. If the amount of an expenditure is not known, furnish an estimate estimate.	ormat	ion may be giver	as su	ıbject
	Transfer Agent's Fees				1,500
	Printing and Engraving Costs			<b>\$</b> _	1,000
	Legal Fees			■\$_	50,000
	Accounting Fees			<b>\$</b> _	0
	Engineering Fees			□ \$_	0
	Sales Commissions (specify finder's fees separately)			<b>-</b> \$_	489,060
	Other expenses (identify)(Miscellaneous)			. = :	\$ 25,000
	Total			<b>-</b> \$_	566,560

4 of 8

C. OFFERING PRICE.	NUMBER OF INVESTORS, EXPENS	SES AND USE OF P	PROCEEDS
b. Enter the difference between the aggreg	gate offering price given in response to F I in response to Part C - Question 4.a. Th	Part C -	\$ 6,957,436
<ol> <li>Indicate below the amount of the adjusted used for each of the purposes shown. If estimate and check the box to the left of equal the adjusted gross proceeds to the above.</li> </ol>	the amount for any purpose is not know the estimate. The total of the payment	n, furnish an	
		Payments to Officers, Directors & Affiliates	Payments To Others
Salaries and fees		. 🗆 \$	\$
Purchase of real estate			\$
Purchase, rental or leasing and installa	ation of machinery and equipment	□ \$	<b>500,000</b>
Construction or leasing of plant buildi	ngs and facilities	<b></b>	🗆 \$
offering that may be used in exchange	ding the value of securities involved in the for the assets or securities of another		;
Repayment of indebtedness		<b></b> \$	\$
Working capital.		. • \$	<b>2,457,436</b>
Other(specify) (clinical trials and relationship)	ated activities and marketing)	<b>=</b> \$0	<b>\$</b> 4,000,000
Column Totals.		. • \$0	<b>\$</b> 6,957,436
Total Payments Listed (column totals	added)	<b>-</b> \$	6,957,436
	D. FEDERAL SIGNATURE		
The issuer has duly caused this notice to be signed the following signature constitutes an undertal written request of its staff, the information full Rule 502.	king by the issuer to furnish to the U.S.	Securities and Exch	ange Commission, upon
Issuer (Print or Type)	Signature	//	ate
Hemispherx Biopharma, Inc.	Campon N Cthe	A A	ugust 16, 2004
Name of Signer (Print or Type)  Ransom W. Etheridge	Title of Signer (Print or Type) Secretary	7	

## ATTENTION